Sustained expression of high levels of human factor IX from human cells implanted within an immunoisolation device into athymic rodents

Human Gene Therapy

Volumn 9, Issue 6, 1998, Pages 879-888

  Brauker, James ^a,b   Frost, Gloria H ^a,e   Dwarki, Varavani ^c,d   Nijjar, Tarlochan ^c   Chin, Richard ^c   Carr Brendel, Victoria ^a   Jasunas, Carol ^a   Hodgett, Debra ^a   Stone, Wendy ^a   Cohen, Lawrence K ^c   Johnson, Robert C ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

^b W L GORE AND ASSOCIATES   (United States)

^c CELL GENESYS INC   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Allegiance Healthcare Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9; POLITEF; POLYESTER; VIRUS VECTOR;

ANIMAL EXPERIMENT; ARTICLE; CELL ISOLATION; CELL TRANSPLANTATION; DEVICE; EPIDIDYMIS FAT; FIBROBLAST CULTURE; GENE THERAPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROMOTER REGION; RAT; RETROVIRUS; SUBCUTANEOUS FAT; TRANSGENE;

ANIMALIA; RODENTIA; UNIDENTIFIED RETROVIRUS;

EID: 17344372252     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1998.9.6-879     Document Type: Article

References (19)

1. AEBISCHER, P., BUSCHER, E., JOSEPH, J., FAVRE, J., LYSAGHT, M., and RUDNICK, S. (1994). Transplantation of polymer encapsulated bovine chromaffin cells in patients suffering from pain resistant to conventional therapies. Transplantation 58, 1275-1277.
2. AL-HENDY, A., HORTELANO, G., TANNENBAUM, G.S., and CHANG, P. (1995). Correlation of the growth defect in dwarf mice with nonautologous microencapsulated myoblasts - an alternate approach to somatic gene therapy. Hum. Gene Ther. 6, 165-175.
3. BARR, E., and LEIDEN, J.M. (1991). Systemic delivery of recombinant proteins by genetically modified myoblasts. Science 254, 1507-1509.
4. BONHAM, L., PALMER, T., and MILLER, D. (1996). Prolonged expression of therapeutic levels of human granulocyte colony-stimulating factor in rats following gene transfer to skeletal muscle. Hum. Gene Ther. 7, 1423-1429.
5. BRAUKER, J., CARR-BRENDEL, V.E., MARTINSON, L.A., CRUDELE, J., JOHNSTON, W.D., and JOHNSON, R.C. (1995). Neovascularization of synthetic membranes directed by membrane architecture. J. Biomed. Mater. Res. 29, 1517-1524.
6. BAUKER, J., MARTINSON, L.A., YOUNG, S.K., and JOHNSON, R.C. (1996). Local inflammatory response around diffusion chambers containing xenografts: Nonspecific destruction of tissues and decreased local vascularization. Transplantation 61, 1671-1677.
7. DAI, Y., ROMAN, M., NAVIAUX, R.K., and VERMA, I.M. (1992). Gene therapy via primary myoblasts: Long-term expression of factor IX protein following transplantation in vivo. Proc. Natl. Acad. Sci. U.S.A. 89, 10892-10895.
8. DHAWAN, J., PAN, L.C., PAVLATH, G.K., TRAVIS, M.A., LANCTOT, A.M., and BLAU, H.M. (1991). Systemic delivery of human growth hormone by injection of genetically engineered myoblasts. Science 254, 1509-1512.
9. DWARKI, V., BELLONI, P., NIJJAR, T., SMITH, J., COUTO, L., RABIER, M., CLIFT, S., BERNS, A., and COHEN, L.K. (1995). Gene therapy for hemophilia A; production of therapeutic levels of human factor VIII in vivo in mice. Proc. Natl. Acad. Sci. U.S.A. 92, 1023-1027.
10. ENGELHARDT, J.F., LITZKY, L., and WILSON, J.M. (1994). Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum. Gene Ther. 5, 1217-1229.
11. FANG, B., EISENSMITH, R.C., LI, X.H.C., FINEGOLD, M.J., SHEDLOVSKY, A., DOVE, W., and WOO, S.L.C. (1994). Gene therapy for phenylketonuria: Phenotypic correction in a genetically deficient mouse model by adenovirus mediated hepatic gene transfer. Gene Ther. 1, 247-254.
12. Food and Drug Administration. (1991). Points to consider in human somatic cell therapy and gene therapy. Hum. Gene Ther. 2, 251-256.
13. Food and Drug Administration. (1996). Regulatory issues: Addendum to the points to consider in human somatic cell and gene therapy (1991). Hum. Gene Ther. 7, 1181-1190.
14. GROSSMAN, M., RAPER, S.E., KOZARSKY, K., STEIN, E.A., ENGELHARDT, J.F., MULLER, D., LUPIEN, P.J., and WILSON, J.M. (1994). Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nature Genet. 6, 335-341.
15. HAMMANG, J.P., EMERICH, D.F., WINN, S.R., LEE, A., LIND-NER, M.D., GENTILE, F.T., DOHERTY, E.J., KORDOWER, J.H., and BAETGE, E.E. (1995). Delivery of neurotrophic factors to the CNS using encapsulated cells: Developing treatments for neurodegenerative diseases. Cell Transplant. 4(S1), S27-S28.
16. HAO, Q., MALIK, P., SALAZAR, R., TANG, H., GORDON, E.M., and KOHN, D.B. (1995). Expression of biologically active human factor IX in human hematopoietic cells after retroviral vector-mediated gene transduction. Hum. Gene Ther. 6, 873-880.
17. HAYFLICK, L. (1979). The cell biology of aging. J. Invest. Dermatol. 73, 8-14.
18. YAO, S.-N., WILSON, J.M., NABEL, E.G., KURACHI, S., HACHIYA, H.L., and KURACHI, K. (1991). Expression of human factor IX in rat capillary endothelial cells: Toward somatic gene therapy for hemophilia B. Proc. Natl. Acad. Sci. U.S.A. 88, 8101-8105.
19. ZHOU, J., DIA, Y., QIU, X., HOU, G., AKIRA, Y., and XUE, J. (1993). Expression of human factor IX cDNA in mice by implants of genetically modified skin fibroblasts from a hemophilia B patient. Sci. China 36, 1082-1092.